Advertisement
Advertisement
DNTH
Dianthus Therapeutics, Inc. Common Stock
79.56
USDSponsored
+1.01
+1.28%
Mar 25, 16:00 UTC -4
Closed
After-Market
79.59
+0.03
+0.04%
DNTH Earnings Reports
Positive Surprise Ratio
DNTH beat 21 of 31 last estimates.
68%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$369.45K
/-$1.08
Implied change from Q4 25 (Revenue/ EPS)
+30.09%
/-24.48%
Implied change from Q1 25 (Revenue/ EPS)
-68.23%
/+31.71%
Dianthus Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 09, 2026, DNTH reported earnings of -1.43 USD per share (EPS) for Q4 25, missing the estimate of -1.09 USD, resulting in a -30.33% surprise. Revenue reached 284.00 thousand, compared to an expected 406.90 thousand, with a -30.20% difference. The market reacted with a +21.52% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -1.08 USD, with revenue projected to reach 369.45 thousand USD, implying an decrease of -24.48% EPS, and increase of 30.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Dianthus Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Dianthus Therapeutics, Inc. Common Stock reported EPS of -$1.43, missing estimates by -30.33%, and revenue of $284.00K, -30.2% below expectations.
How did the market react to Dianthus Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 21.52%, changed from $65.20 before the earnings release to $79.23 the day after.
When is Dianthus Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Dianthus Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Dianthus Therapeutics, Inc. Common Stock is expected to report EPS of -$1.08 and revenue of $369.45K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement